0001807120false00018071202025-01-132025-01-13

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 13, 2025

 

 

Design Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-40288

82-3929248

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

6005 Hidden Valley Road

Suite 110

 

Carlsbad, California

 

92011

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: (858) 293-4900

 

N/A

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, $0.0001 par value per share

 

DSGN

 

Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 


 

Item 7.01

Regulation FD Disclosure.

 

On January 13, 2025, Design Therapeutics, Inc. (the “Company”) updated its corporate presentation for use in meetings with investors, analysts and others. A copy of the updated presentation is attached as Exhibit 99.1 to this Current Report on Form 8-K.

 

The information under this Item 7.01 of this Current Report on 8-K, including Exhibit 99.1, is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933, as amended, whether filed before or after the date hereof and regardless of any general incorporation language in such filing.

Item 9.01

Financial Statements and Exhibits.

 

(d) Exhibits

Exhibit No.

 

Description

 

99.1

Company Presentation

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

 


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

 

Design Therapeutics, Inc.

 

 

 

 

Date:

January 13, 2025

By:

/s/ Pratik Shah, Ph.D.

 

 

 

Pratik Shah, Ph.D.
President, Chief Executive Officer and Chairperson

 


Exhibit 99.1

img267412975_0.jpg

 


 

img267412975_1.jpg

 


 

img267412975_2.jpg

 


 

img267412975_3.jpg

 


 

img267412975_4.jpg

 


 

img267412975_5.jpg

 


 

img267412975_6.jpg

 


 

img267412975_7.jpg

 


 

img267412975_8.jpg

 


 

img267412975_9.jpg

 


 

img267412975_10.jpg

 


 

img267412975_11.jpg

 


 

img267412975_12.jpg

 


 

img267412975_13.jpg

 


 

img267412975_14.jpg

 


 

img267412975_15.jpg

 


 

img267412975_16.jpg

 


 

img267412975_17.jpg

 


 

img267412975_18.jpg

 


 

img267412975_19.jpg

 


 

img267412975_20.jpg

 


 

img267412975_21.jpg

 


 

img267412975_22.jpg

 


 

img267412975_23.jpg

 


 

img267412975_24.jpg

 


 

img267412975_25.jpg

 


 

img267412975_26.jpg

 


 

img267412975_27.jpg

 


 

img267412975_28.jpg

 


 

img267412975_29.jpg

 


 

img267412975_30.jpg

 


 

img267412975_31.jpg

 


 

img267412975_32.jpg

 


 

img267412975_33.jpg

 


 

img267412975_34.jpg

 


 

img267412975_35.jpg


 

img267412975_36.jpg


 

img267412975_37.jpg

 


 

img267412975_38.jpg

 


 

img267412975_39.jpg

 


 

img267412975_40.jpg

 


 

 

img267412975_41.jpg

 

 


 

img267412975_42.jpg

 


 

img267412975_43.jpg

 


 

img267412975_44.jpg

 


 

img267412975_45.jpg

 


 

img267412975_46.jpg

 


v3.24.4
Document And Entity Information
Jan. 13, 2025
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jan. 13, 2025
Entity Registrant Name Design Therapeutics, Inc.
Entity Central Index Key 0001807120
Entity Emerging Growth Company true
Entity File Number 001-40288
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 82-3929248
Entity Address, Address Line One 6005 Hidden Valley Road
Entity Address, Address Line Two Suite 110
Entity Address, City or Town Carlsbad
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92011
City Area Code (858)
Local Phone Number 293-4900
Entity Information, Former Legal or Registered Name N/A
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Ex Transition Period true
Title of 12(b) Security Common Stock, $0.0001 par value per share
Trading Symbol DSGN
Security Exchange Name NASDAQ

Design Therapeutics (NASDAQ:DSGN)
Gráfico Histórico do Ativo
De Dez 2024 até Jan 2025 Click aqui para mais gráficos Design Therapeutics.
Design Therapeutics (NASDAQ:DSGN)
Gráfico Histórico do Ativo
De Jan 2024 até Jan 2025 Click aqui para mais gráficos Design Therapeutics.